// healthcare
AI in Healthcare & Life Sciences
Most deployed healthcare AI is still back-office and interface-level, not diagnostic — but AI drug discovery is now heading for public markets.
standing summary updated September 25, 2026
Where AI in healthcare and life sciences actually stands
Healthcare AI's commercially deployed surfaces are still administrative and interface-level rather than diagnostic. The largest is the back office — billing, coding, prior authorisation and the paperwork layer sitting between a clinician and getting paid. Commure, a $7 billion startup, is built around automating exactly that, and R1, a revenue cycle processor handling over 600 million transactions a year, has agreed to buy Humata Health specifically for AI-powered prior authorisations. The second surface is the patient portal: Oracle Health's AI-backed portal is generally available in the US, built on OpenAI foundation models, wired into Oracle's EHR, and offering record review, provider engagement, appointment scheduling and AI-generated explanations of medical jargon. The third is clinician-facing summarisation inside the chart — Epic's Ergo Visit compiles patient information from its EHR and other sources into an outpatient summary, with Ochsner Health the first health system to implement it.
Who ends up running that software is decided by delivery shape more than by capability. On the Oracle and Epic stacks it arrives as a feature of a system the hospital already runs rather than as a product it went out and chose. The alternative is acquisition: prior authorisation is where provider revenue stalls, and a processor at R1's transaction volume buying that capability instead of building it is a make-or-buy marker for anyone budgeting revenue-cycle automation. The same consolidation runs one layer out at the point-solution level, where Sword Health's all-cash acquisition of Headspace parent OrangeDot was due to close on 14 September — that date has now passed and nothing since has confirmed the close. Sitting above the acquirer set is Anthropic, hiring a corporate development lead in biopharma to source and execute acquisitions, investments and strategic partnerships, which would put a frontier lab on the buy side of life sciences rather than only selling models into it. That is still one job posting and no transaction, so the honest read is a stated intention to shop rather than a changed market. Inference
The layer that finally moved is drug discovery, which had been quiet for weeks. Iambic Therapeutics — Nvidia-backed, based in San Diego, founded in 2019 — signed an R&D partnership with AbbVie and shipped the next generation of Enchant, one of its main models, then filed to go public a day later with new detail on its own pipeline programmes. Two things are worth separating. The AbbVie deal came with no disclosed terms, so it carries no price signal; what it shows is the continuing pattern of large pharma reaching for AI discovery capability through partnership rather than building it in house. The filing is the more consequential event, because going public forces the disclosure this corner of the industry has mostly avoided: pipeline stage, spend, and what the models have actually produced. Endpoints News reads it as a maturation marker for AI biotech, and for anyone evaluating an AI discovery partner it should eventually yield a rare set of comparable numbers — but a filing is not a listing, and those numbers are not in public hands yet. Inference
Underneath all of this, consent is unresolved and the regulatory floor is still empty. Pew Research Center puts numbers on the first: nearly three-quarters of US adults say it is extremely or very important that providers disclose AI use, 53% say they have little or no say over it, and nearly half are unsure whether it has already been used in their care. That last figure fits the deployment picture, because every surface described above is one a patient never sees — an ambient scribe, a prior authorisation decision, a model that proposed a molecule years before any trial. Inference On the regulatory side, the FDA's head of digital health policy has said generative AI device guidance is coming but gave no timing and no scope, the report is single-sourced, and device guidance would reach neither the administrative software where most of the deployed footprint sits nor preclinical discovery models. Inference The evidence hole has not closed either: Epic's launch coverage carried no accuracy or evaluation data, its quoted footprint of one health system and five outside physicians described an announcement rather than an installed base, and this week produced no outcomes data, no regulator action and no checkable accuracy claim — a partnership without terms and an IPO filing were the whole of it. On the current record the sector's AI story remains about administering, scheduling and explaining care rather than delivering it, with drug discovery now the one place where the claims are about to be tested in public.
// Big moves
2026-W39Iambic Therapeutics, the Nvidia-backed AI drug discovery firm, filed to go public, disclosing new details on its own pipeline programmes. Endpoints News frames it as the latest maturation marker among AI-focused biotech startups — and a filing forces the pipeline, spend and results disclosure the field has mostly avoided.
CorroboratedEndpoints Newssource →
AbbVie signed an R&D partnership with Iambic as the San Diego firm, founded in 2019, released the next generation of Enchant, one of its main AI models. No terms were disclosed, so the signal is the pattern — large pharma reaching for AI discovery capability through partnership rather than building it — not the price.
UnverifiedEndpoints Newssource →
A named pharma partner landing a day before the IPO filing was reported reads as pipeline validation aimed at public-market investors — though neither report says the two were coordinated, and the undisclosed AbbVie terms mean the partnership cannot be valued.
InferenceEndpoints Newssource →
// Daily stories
2026-09-25
CMS administrator Oz says AI will inflate healthcare costs before it lowers themCorroboratedHealthcare Dive2026-09-24At Oracle's annual health and life sciences summit, CMS Administrator Mehmet Oz said AI will be inflationary in the short term because it will turbocharge the ability of current billing systems to work more effectively. Researchers have observed rising costs tied to AI in coding and billing.
why it matters
The official who runs Medicare payment is signalling that AI's first effect is higher billing throughput. ROI cases built on cost reduction should be stress-tested against coding-driven spend and likely payer scrutiny.
2026-09-23
Nvidia-backed AI drug discovery firm Iambic Therapeutics files to go publicCorroboratedEndpoints News2026-09-22Iambic Therapeutics has filed to go public, per Endpoints News, which frames it as the latest example of maturation among AI-focused biotech startups. The San Diego company disclosed new details on its own pipeline programmes.
why it matters
An IPO filing forces the disclosure AI drug discovery has mostly avoided: pipeline stage, spend, and what the models have actually produced. For teams evaluating AI partners, it is a rare set of comparable numbers.
2026-09-22
AbbVie signs an R&D partnership with Iambic as the AI drug-discovery firm ships a new Enchant modelUnverifiedEndpoints News2026-09-21Iambic Therapeutics signed an R&D partnership with AbbVie and released the next generation of Enchant, one of its main AI models, Endpoints News reported. The San Diego company was founded in 2019. No terms were given.
why it matters
Large pharma keeps reaching for AI discovery capability through partnership rather than building it in house. With no terms disclosed, the signal is the pattern, not the price.
2026-09-11
ARPA-H kicks off ADVOCATE, putting millions into health tech firms building AI agentsUnverifiedEndpoints News2026-09-10ARPA-H, the federal agency that funds breakthrough health technologies, has kicked off a programme called ADVOCATE, which provides millions of dollars to health tech companies to build AI agents, Endpoints News reported.
why it matters
Federal money is now underwriting agentic tooling in health, which moves some build risk off provider and sponsor balance sheets. Worth checking whether ADVOCATE's scope overlaps work you were planning to fund internally.
2026-09-09
Anthropic posts for a biopharma corporate development lead to run acquisitions and partnershipsCorroboratedEndpoints News2026-09-08Anthropic is hiring a corporate development lead in biopharma to "source and execute acquisitions, investments, and strategic partnerships," according to a job posting reported by Endpoints News, which reads the listing as confirming the company's biotech dealmaking ambitions.
why it matters
A frontier lab buying into life sciences, rather than only selling models to it, would change the partner and acquirer landscape. It is one job posting — but worth watching what it actually buys.
2026-08-28
Pew: nearly three-quarters of US adults want providers to disclose when AI is used in their careCorroboratedHealthcare Dive2026-08-27A Pew Research Center survey published this week found nearly three-quarters of US adults say it is extremely or very important that providers disclose AI use, while 53% say they have little or no say over it and nearly half are unsure whether it has already been used in their care.
why it matters
Patient disclosure is drifting from a compliance checkbox toward a consent expectation. Worth deciding now how ambient scribes and imaging triage get surfaced to patients — the survey suggests most do not know it is happening.
2026-08-27
Sword Health to buy Headspace all-cash, per a state filing, with the close set for Sept 14CorroboratedHealthcare Dive2026-08-26Headspace parent OrangeDot told Massachusetts regulators on 22 July that it is seeking to be acquired by Sword Health in an all-cash deal expected to close on 14 September, Healthcare Dive reports. Terms were not disclosed and neither company commented.
why it matters
Employers and payers buying point solutions may find their virtual care and mental health vendors merging into one contract. If you hold both, worth reviewing renewal and data terms before the close date.
2026-08-25
FDA's digital health policy head says generative AI device guidance is comingUnverifiedSTAT2026-08-24STAT reports the FDA expects to issue guidance on its policies for generative AI devices, according to Rick Abramson, the agency's head of digital health policy. No timing or scope was given.
why it matters
Teams building generative AI tools still have no FDA guidance to design against. Worth watching what scope the agency defines before committing to a submission pathway or a launch date.
2026-08-21
R1 to buy Humata Health to automate insurer prior authorisations; terms undisclosedCorroboratedHealthcare Dive2026-08-20Revenue cycle firm R1 has agreed to acquire Humata Health, which specialises in AI-powered prior authorisations, with the deal expected to close in Q3. Humata's team will then integrate its technology into R1's revenue cycle platform. An R1 spokesperson declined to share financial terms.
why it matters
Prior authorisation is where provider revenue stalls. A processor handling over 600 million transactions a year buying the capability rather than building it is a make-or-buy marker for anyone budgeting revenue-cycle automation.
2026-08-20
Epic launches Ergo Visit for outpatient clinicians, with Ochsner Health the first to implementCorroboratedHealthcare Dive2026-08-19At its annual meeting in Wisconsin, Epic launched Ergo Visit, a tool that compiles patient information from its EHR and other sources into a summary for outpatient clinicians. Ochsner Health is the first health system to implement it, and five physicians outside the system are piloting it.
why it matters
Anything Epic ships lands on every health system's roadmap by default. The question for CIOs is whether outpatient summarisation displaces a point solution you already bought, and what evidence Epic offers on accuracy.
2026-08-13
Oracle Health's AI patient portal, built on OpenAI models, goes generally available in the USCorroboratedHealthcare Dive2026-08-12Oracle said Wednesday its AI-backed patient portal is now generally available in the US. Built on OpenAI foundation models and integrated with Oracle's EHR, it lets patients review records, engage providers, schedule appointments and get AI-generated explanations of medical jargon.
why it matters
Patient-facing generative AI is arriving as an EHR feature rather than a pilot, which shifts the question from whether to deploy to who reviews what patients are told. Contract terms decide whether you already own it.
2026-08-12
STAT reports from inside Commure, a $7 billion startup automating healthcare's administrative tasks, on what it calls the messy realities of the effort. Article is behind STAT+.
why it matters
Administrative automation, not diagnosis, is where healthcare AI revenue is concentrating. It is also where the failure modes are least visible to patients.
// Track AI in Healthcare & Life Sciences
One email a week on what actually changed — in healthcare & life sciences and across the frontier. Verified, labelled, no hype.